엑소좀 요법 시장 : 치료법 유형별, 대상 적응증별, 치료 분야별, 투여 경로별, 지역별 - 동향 및 세계 예측(-2040년)

EXOSOME THERAPY MARKET: OVERVIEW

As per Roots Analysis, the global exosome therapy market is estimated to grow from USD 32 million in the current year to USD 1,405 million by 2040, registering a CAGR of 41.1% across the forecast period.

Exosome Therapy Market: Growth and Trends

Extracellular vesicle-based therapeutics have moved from an academic curiosity to a closely watched clinical modality. Their appeal lies in target specificity, enhanced tissue regeneration and reduced systemic inflammation relative to conventional biologics, characteristics that have drawn both industry sponsors and non-industry research groups into active development programs. A review of over 200 published studies evaluating mesenchymal stem cell derived exosomes for preclinical use reported measurable benefit in more than 70% of cases, a data point that continues to anchor investor and licensing interest in the space.

The market growth momentum has been reinforced by a steady rise in investigational new drug filings since the COVID-19 pandemic, as sponsors seek regulatory clearance to move exosome candidates into human trials. For distributors and channel partners, this represents an early but fast-widening window to establish positioning ahead of the anticipated wave of clinical and commercial launches.

Growth Drivers: Factors Fueling Market Expansion

Growth in the exosome therapy market is being driven by rising disease burden across ophthalmic, dermatological, musculoskeletal, and rectal disorders. Further, expanding research and development activity... and increasing government funding directed at exosome production and characterization infrastructure. Intra-ocular administration is emerging as a particularly active route, supported by a growing body of clinical evidence in retinal and ophthalmic indications. The broader shift of pharmaceutical R&D investment toward emerging economies is expected to add further momentum, widening the addressable base for distribution and supply chain partners over the forecast period.

Market Challenges: Critical Barriers Hindering Progress

Despite favorable long-term growth, exosome therapy developers continue to face technical and commercial challenges. Weak therapy preparations, bacterial contamination risk, and the presence of non-exosomal components complicate manufacturing consistency. Further, the inherent heterogeneity of extracellular vesicles makes standardized quantification and characterization difficult across cell sources. On the commercial side, the withdrawal of seven pipeline candidates due to enrolment and funding constraints, illustrate the financing risk that stakeholders evaluating this market need to underwrite.

Exosome Therapy Market: Key Insights

The report delves into the current state of the Exosome Therapy market and identifies potential growth opportunities for distribution partners, channel intermediaries, and service integrators. Some key findings include:

• The exosome therapeutics pipeline presently features close to 120 therapeutic candidates, with more than 40% already in clinical stage development, indicating that the market's commercial inflection point is approaching faster than headline revenue figures suggest.
• Seven exosome therapies, including EXOMSC-COV19 (Dermama Biotech Lab), Dex2 (Gustave Roussy Institute) and SF-MSC-EX (Osmangazi University), are currently in advanced clinical stages, forming a near-term watchlist for licensing and distribution partners.
• Approximately 30% of pipeline candidates target oncology indications, including breast, lung, colon cancer and melanoma, positioning exosomes as an emerging targeted drug delivery vehicle in a therapeutic area that already commands significant specialty distribution infrastructure.
• More than 60 pharmaceutical companies and academic or research institutes are actively engaged in exosome therapeutic development, reflecting a fragmented, partnership-driven ecosystem well suited to distributors offering regulatory, logistics and go-to-market support.
• Strategic in-licensing activity, such as Coya Therapeutics' 2022 agreement with Carnegie Mellon University for exosome-polymer hybrid delivery technology illustrates how platform technology access is becoming a differentiator among developers, an important due-diligence signal for investors and partners alike.
• EVerZom raised EUR 10 million in a funding round to advance exosome-based biotherapies targeting inflammatory diseases and to initiate clinical development of its pipeline programs.
• Regulatory scrutiny increased around non-compliant exosome product marketing, reinforcing the importance of IND-backed clinical development pathways for commercial legitimacy in this space.

Exosome Therapy Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Therapeutic

• Allogeneic
• Autologous

By Target Disease Indication

• Degenerative Meniscal Injury
• Dystrophic Epidermolysis Bullosa
• Fistula Perianal
• Retinitis Pigmentosa

By Therapeutic Area

• Dermatological Disorders
• Musculoskeletal Disorders
• Ophthalmic Diseases
• Rectal Disorders

By Type of Formulation

• Liquid
• Aerosol

By Route of Administration

• Fistula Tract
• Intra-articular
• Intra-ocular

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

Exosome Therapy Market: Key Segments

Ophthalmic Diseases Lead the Market

Based on Roots Analysis market assessment, ophthalmic diseases are expected to account for the largest share of therapeutic area revenues. This highest share is supported by a robust clinical pipeline targeting retinal and ocular surface disorders. In addition, the relatively advanced development of intra-ocular delivery platforms, which enable localized administration, improve therapeutic exposure at the target site, and reduce systemic adverse effects, supporting the highest share. Together, these advantages position ophthalmology as one of the most commercially promising applications for exosome-based therapeutics.

Intra-Ocular Route of Administration Dominates the Market

In terms of route of administration, exosome therapeutics designed for intra-ocular delivery are expected to register higher CAGR throughout the forecast period. This is primarily due to the growing focus on ophthalmic disorders, where localized ocular delivery enables higher therapeutic concentrations at the target site while minimizing systemic exposure, making it a well-suited approach for exosome-based therapies.

Oncology Dominates the Market

Based on the Roots Analysis market report, oncology dominates the market. This can be attributed to the growing focus on oncology, with nearly 30% of exosome therapeutics currently under development targeting cancers such as breast cancer, lung cancer, melanoma, and colorectal cancer. This trend reflects the increasing interest in using exosomes as targeted drug delivery vehicles. Although the segment remains in the early stages of clinical development, its robust pipeline highlights strong long-term commercial and partnership opportunities for stakeholders positioned ahead of market maturation.

Asia-Pacific Dominates the Market and Registers Higher CAGR

Based on the proprietary report, Asia-Pacific holds the highest share and is likely to remain dominant in the future. This growth is being driven by increasing investments in regenerative medicine and advanced biologics, a rapidly expanding pipeline of exosome-based therapeutics, and the growing number of clinical trials across China, Japan, South Korea, and India.

Governments across the region are strengthening support for cell and gene therapy innovation through funding initiatives, translational research programs, and evolving regulatory frameworks. These fundings initiatives will accelerate the progression of exosome candidates toward commercialization.

Moreover, the emergence of regional biomanufacturing capabilities and strategic collaborations to scale exosome production is increasing demand for specialized logistics, GMP-compliant manufacturing support, and temperature-controlled distribution networks, positioning Asia-Pacific as a key future hub for exosome therapy development and commercialization.

Example Players in Exosome Therapy Market

• Cellular Biomedicine Group
• Coya Therapeutics
• Curexsys
• EV Therapeutics
• Evox Therapeutics
• ExoCoBio
• ILIAS Biologics
• Rion
• SHIFTBIO

Expert Interview and Industry Insights

The opinions and insights presented in the full study were shaped by discussions with multiple stakeholders across the exosome therapeutics value chain. The research report features detailed transcripts of interviews held with the following industry participants:

• Chief Business Officer, Small Company, US
• Chief Business Officer, Mid-Sized Company, South Korea
• R&D and Innovation Manager, Very Small Company, Portugal

EXOSOME THERAPY MARKET: RESEARCH COVERAGE

• Market Landscape: A detailed assessment of the current pipeline, segmented by phase of development, technology platform, type of payload, derived source, target disease indication, therapeutic area, route of administration, type of therapy, dosing frequency and line of treatment, along with a profile of developer companies by year of establishment, size and headquarters location.
• Company Profiles: In-depth profiles of key exosome therapeutics developers, including company overview, product portfolio and recent developments and future outlook.
• Drug Profiles: Elaborate profiles of the leading exosome therapy candidates in the highest phase of development, including product portfolio and detailed clinical trial information.
• Clinical Trial Analysis: A detailed analysis of completed and ongoing clinical trials by trial status, registration year, sponsor type, study design, patient enrolment, age category, trial location, and geography.
• Academic Grant Analysis: An in-depth analysis of academic grants awarded for exosome therapeutics research since 2017, covering funding institute, support period, purpose of grant, recipient organization, and grant activity code.
• Global Event Analysis: An assessment of global industry events related to exosome therapeutics, by year, platform, region, active organizers, speakers, and participant profile.
• Partnerships and Collaborations: An analysis of research, licensing, manufacturing, product development, and M&A partnerships inked in this space since 2017, by partnership type, technology platform, target indication and geography.
• Funding and Investment Analysis: A detailed analysis of grant, seed, venture capital, IPO, secondary offering, and debt financing instances since 2017, by amount invested, purpose, target indication, therapeutic area, and geography.
• Start-Up Health Indexing: A proprietary Roots Analysis framework assessing start-ups by pipeline strength, pipeline maturity, indication diversity, partnership activity, and financial support.
• Case Study (Exosome Development and Manufacturing Companies): A focused assessment of service providers offering isolation, characterization, purification, engineering, and targeted delivery capabilities, segmented by scale of operation and scalability.
• Drug Failure Analysis: An analysis of exosome therapeutics that were discontinued during clinical development, by target indication, route of administration, sponsor type, and reason for failure.
• Market Sizing and Opportunity Analysis: Year-wise global and regional (North America, Europe, Asia-Pacific, Rest of the World) market projections (2029-2040) segmented by type of therapeutic, target disease indication, therapeutic area, route of administration and leading drug candidates, presented under conservative, base, and optimistic forecast scenarios.

Key Questions Answered in this Report

• What is exosome therapy and how does it compare with conventional biologic modalities?
• What is the current and future size of the exosome therapy market?
• What is the CAGR of the exosome therapy market through 2040?
• Which companies and academic institutes are leading exosome therapeutics development?
• Which target indications and therapeutic areas are expected to generate the most revenue?
• Which route of administration is likely to dominate the market, and why?
• Which region is expected to register the fastest growth, and what is driving it?
• What are the primary technical and financing risks facing exosome therapy developers?
• What opportunities exist for distributors, logistics partners and investors entering this space?

Reasons to Buy this Report

This report is designed to give distributors, channel partners, and investors a decisive analytical edge in a fast-consolidating market. Its core differentiators include:

• Top-Down and Bottom-Up Triangulated Forecasting: Market estimates for Till 2040 are built using a hybrid methodology that cross-validates top-down macro assessments of disease burden and pipeline maturity against bottom-up, candidate-level clinical and commercial data, minimizing forecast bias.
• Comprehensive Database Cover Across 27 Chapters: Comprehensive coverage spanning market sizing, competitive landscape, clinical trial activity, academic grant funding, global events, partnerships, financing, and drug failure analysis, with dedicated regional chapters for North America, Europe, Asia-Pacific, and Rest of the World.
• Primary Research-Backed Insights: Findings are validated through direct interviews with Chief Business Officers and R&D leaders across small and mid-sized exosome developers, ensuring conclusions reflect real operating conditions rather than desk research alone.
• Six-Parameter Actionable Segmentation: Type of therapeutic, target disease indication, therapeutic area, type of formulation, route of administration and geography enable precise opportunity sizing for any go-to-market, licensing, or investment thesis.
• Three-Scenario Forecast Modeling: Conservative, base and optimistic projections account for the funding and clinical-execution risk that has historically affected early-stage exosome developers, supporting more robust investment and partnership decisions.
• Searchable Company and Grant Database: An easily searchable Excel database of all companies, academic institutes, and grant recipients active in exosome therapeutics development, purpose-built for business development and targeted outreach.

Additional Benefits

• Complementary PPT Insights Pack
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2 Market Segmentation
• 1.3. Research Methodology
• 1.4. Key Questions Answered
• 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Overview of Exosomes
  • 3.1.1. Types of Extracellular Vesicles
  • 3.1.1. Potential Sources of Exosomes
• 3.2. Exosome Biogenesis
  • 3.2.1. Exosome Formation and Development Process
  • 3.2.2. Secretion of Exosomes
• 3.3. Applications of Exosomes
• 3.4. Mechanism of Exosome Therapy
  • 3.4.1. Exosome Drug Therapy
  • 3.4.2. Exosome RNAi Therapy
  • 3.4.3. Exosome Immunotherapy
• 3.5. Advantages of Exosome Therapy
• 3.6. Risks and Future Perspectives Associated with Exosome Therapeutics

4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE

• 4.1. Analysis Methodology and Key Parameters
• 4.2. Exosome Therapeutics Market Landscape
  • 4.2.1. Analysis by Phase of Development
  • 4.2.2. Analysis by Technology Platform
  • 4.2.3. Analysis by Type of Payload
  • 4.2.4. Analysis by Derived Source
  • 4.2.5. Analysis by Target Disease Indication(s)
  • 4.2.6. Analysis by Therapeutic Area
  • 4.2.7. Analysis by Phase of Development and Therapeutic Area
  • 4.2.8. Analysis by Therapeutic Area and Route of Administration
  • 4.2.9. Analysis by Route of Administration
  • 4.2.10 Analysis by Area of Application
  • 4.2.11. Analysis by Type of Therapy
  • 4.2.12. Analysis by Dosing Frequency
  • 4.2.13. Analysis by Type of Therapy (By Method of Composition)
  • 4.2.14. Analysis by Line of Treatment
• 4.3. Exosome Therapy Developers
  • 4.3.1. Analysis by Year of Establishment
  • 4.3.2. Analysis by Company Size
  • 4.3.3. Analysis by Location of Headquarters
  • 4.3.4. Most Active Players: Analysis by Number of Therapeutics

5. EXOSOME THERAPY: COMPANY PROFILES

• 5.1. Coya Therapeutics
  • 5.1.1. Company Overview
  • 5.1.2. Product Portfolio
  • 5.1.3. Recent Developments and Future Outlook
• 5.2. Evox Therapeutics
  • 5.2.1. Company Overview
  • 5.2.2. Product Portfolio
  • 5.2.3. Recent Developments and Future Outlook
• 5.3. Curexsys
  • 5.3.1. Company Overview
  • 5.3.2. Product Portfolio
  • 5.3.3. Recent Developments and Future Outlook
• 5.4. EV Therapeutics
  • 5.4.1. Company Overview
  • 5.4.2. Product Portfolio
  • 5.4.3. Recent Developments and Future Outlook
• 5.5. SHIFTBIO
  • 5.5.1. Company Overview
  • 5.5.2. Product Portfolio
  • 5.5.3. Recent Developments and Future Outlook

6. EXOSOME THERAPY: DRUG PROFILES

• 6.1. AEGLE Therapeutics
  • 6.1.1. Company Overview
  • 6.1.2. AGLE-102: Product Portfolio
    • 6.1.2.1. AGLE-102: Clinical Trial Information
  • 6.1.3. Recent Developments and Future Outlook
• 6.2. AVEM Healthcare
  • 6.2.1. Company Overview
  • 6.2.2. Ardoxso: Product Portfolio
    • 6.2.2.1. Ardoxso: Clinical Trial Information
  • 6.2.3. Recent Developments and Future Outlook
• 6.3. Cellular Biomedicine Group
  • 6.3.1. Company Overview
  • 6.3.2. Financial Information
  • 6.3.3. haMPC-Exos: Product Portfolio
    • 6.3.3.1. haMPC-Exos: Clinical Trial Information
  • 6.3.4. hMSC-Exos: Product Portfolio
    • 6.3.4.1. hMSC-Exos: Clinical Trial Information
  • 6.3.5. Undisclosed Drug 1: Product Portfolio
    • 6.3.5.1. Undisclosed Drug 1: Clinical Trial Information
  • 6.3.6. Recent Developments and Future Outlook
• 6.4. OBCTCD24
  • 6.4.1. Company Overview
  • 6.4.2. CovenD24: Product Portfolio
    • 6.4.2.1. CovenD24: Clinical Trial Information
  • 6.4.3. Recent Developments and Future Outlook
• 6.5. ReNeuron
  • 6.5.1. Company Overview
  • 6.5.2. Financial Information
  • 6.5.3. Undisclosed Drug 1: Product Portfolio
    • 6.5.3.1. Undisclosed Drug 1: Clinical Trial Information
  • 6.5.4. Recent Developments and Future Outlook
• 6.6. Stem Cell Medicine
  • 6.6.1. Company Overview
  • 6.6.2. Undisclosed Drug 1: Product Portfolio
  • 6.6.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

• 7.1. Analysis Methodology and Key Parameters
• 7.2. Exosome Therapeutics: List of Clinical Trials
  • 7.2.1. Analysis by Trial Status
  • 7.2.2. Analysis by Trial Registration Year
  • 7.2.3. Analysis by Sponsor / Collaborator
  • 7.2.4. Analysis by Trial Registration Year and Type of Study
  • 7.2.5. Analysis by Trial Registration Year and Trial Status
  • 7.2.6. Analysis by Annual Number of Patients Enrolled
  • 7.2.7. Analysis by Study Design
  • 7.2.8. Analysis by Age Category
  • 7.2.9. Analysis by Phase of Development and Trial Status
  • 7.2.10. Analysis by Phase of Development and Patients Enrolled
  • 7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials
  • 7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials
  • 7.2.13. Analysis by Trial Location
  • 7.2.14. Analysis by Trial Status and Geography
  • 7.2.15. Analysis by Trial Status, Patients Enrolled and Geography

8. ACADEMIC GRANT ANALYSIS

• 8.1. Analysis Methodology and Key Parameters
• 8.2. Exosome Therapeutics: List of Academic Grants
• 8.3. Analysis by Year of Grants Awarded
• 8.4. Analysis by Amount Awarded per Year
• 8.5. Analysis by Type of Funding Institute Center
• 8.6. Analysis by Support Period
• 8.7. Analysis by Purpose of Grant
• 8.8. Word Cloud Analysis: Emerging Focus Area
• 8.9. Analysis by Grant Activity Code
• 8.10. Analysis by Location of Recipient Organizations
• 8.11. Popular Recipient Organizations: Analysis by Number of Grants
• 8.12. Popular Recipient Organizations: Analysis by Amount Awarded
• 8.13. Analysis by Type of Recipient Organization
• 8.14. Analysis by Study Section
• 8.15. Analysis by Type of Grant Application
• 8.16. Analysis by Funding Institute Center and Support Year

9. GLOBAL EVENT ANALYSIS

• 9.1. Chapter Overview
• 9.2. Scope and Methodology
• 9.3. List of Global Events Related to Exosomes
  • 9.3.1. Analysis by Year of Event
  • 9.3.2. Analysis by Event Platform
  • 9.3.3. Analysis by Type of Event
  • 9.3.4. Analysis by Region
  • 9.3.5. Most Active Organizers: Analysis by Number of Events
  • 9.3.6. Most Active Speakers: Analysis by Number of Events
  • 9.3.7. Most Active Industry Participants: Analysis by Number of Events
  • 9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
  • 9.3.9. Analysis by Designation of Participant
  • 9.3.10. Analysis by Affiliated Department of Participant
  • 9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area

10. PARTNERSHIPS AND COLLABORATIONS

• 10.1. Chapter Overview
• 10.2. Partnership Models
• 10.3. Exosome Therapeutics: List of Partnerships and Collaborations
  • 10.3.1. Analysis by Year of Partnership
  • 10.3.2. Analysis by Type of Partnership
  • 10.3.3. Analysis by Year and Type of Partnership
  • 10.3.4. Analysis by Company and Type of Partnership
  • 10.3.5. Analysis by Type of Technology Platform
  • 10.3.6. Analysis by Type of Partner
  • 10.3.7. Most Active Players: Analysis by Number of Partnerships
  • 10.3.8. Word Cloud Analysis: Emerging Focus Areas
  • 10.3.9. Analysis by Target Disease Indication(s)
  • 10.3.10. Analysis by Therapeutic Area
  • 10.3.11. Analysis by Therapeutic Area and Type of Partnership
  • 10.3.12. Regional Distribution of Partnerships
  • 10.3.13. Distribution by Geography

11. FUNDING AND INVESTMENT ANALYSIS

• 11.1. Analysis Methodology and Key Parameters
• 11.2. Type of Funding
• 11.3. Exosome Therapeutics: List of Funding Instances
• 11.4. Analysis by Year of Funding
• 11.5. Analysis by Amount Invested
• 11.6. Analysis by Type of Funding
• 11.7. Analysis by Type of Funding and Amount Invested
• 11.8. Analysis by Purpose of Funding
• 11.9. Analysis by Target Disease Indication(s)
• 11.10. Analysis by Therapeutic Area
• 11.11. Most Active Players: Analysis by Number of Funding Instances
• 11.12. Most Active Players: Analysis by Amount Raised
• 11.13. Active Investors: Analysis by Number of Funding Instances
• 11.14. Distribution by Geography
• 11.15. Summary of Funding Activity

12. START-UP HEALTH INDEXING

• 12.1. Analysis Methodology and Key Parameters
• 12.2. Analysis by Pipeline Strength
• 12.3. Analysis by Pipeline Maturity
• 12.4. Analysis by Indication Diversity
• 12.5. Analysis by Number of Partnerships
• 12.6. Analysis by Financial Support
• 12.7. Start-up Health Indexing: Roots Analysis Perspective
• 12.8. Most Active Start-ups

13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING COMPANIES

• 13.1. Chapter Overview
• 13.2. Exosome Development and Manufacturing Companies Landscape
  • 13.2.1. Analysis by Year of Establishment
  • 13.2.2. Analysis by Company Size
  • 13.2.3. Analysis by Location of Headquarters
  • 13.2.4. Analysis by Location of Headquarters and Company Size
• 13.3. Analysis by Type of Service(s) Offered
  • 13.3.1. Analysis by Method of Isolation
  • 13.3.2. Analysis by Method of Purification
  • 13.3.3. Analysis by Method of Characterization
  • 13.3.4. Analysis by Method of Exosome Manufacturing
  • 13.3.5. Analysis by Scale of Operation
  • 13.3.6. Analysis by Scalability

14. DRUG FAILURE ANALYSIS

• 14.1. Methodology and Key Parameters
• 14.2. Exosome Therapeutics: List of Failed Drug Candidates
  • 14.2.1. Analysis by Trial Start and Discontinuation Year
  • 14.2.2. Analysis by Trial Status of Discontinuation
  • 14.2.3. Analysis by Target Disease Indication(s)
  • 14.2.4. Analysis by Route of Administration
  • 14.2.5. Analysis by Type of Sponsor
  • 14.2.6. Analysis by Reasons for Drug Failure
  • 14.2.7. Word Cloud Analysis: Emerging Focus Area

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

• 15.1. Forecast Methodology and Key Assumptions
• 15.2. Global Exosome Therapy Market, Till 2040
  • 15.2.1. Exosome Therapy Market for Allogeneic Therapy, Till 2040 (USD Million)
  • 15.2.2. Exosome Therapy Market for Autologous Therapy, Till 2040 (USD Million)
  • 15.2.3. Exosome Therapy Market for Degenerative Meniscal Injury, 2031-2040 (USD Million)
  • 15.2.4. Exosome Therapy Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)
  • 15.2.5. Exosome Therapy Market for Fistula Perianal, Till 2040 (USD Million)
  • 15.2.6. Exosome Therapy Market for Retinitis Pigmentosa, Till 2040 (USD Million)
  • 15.2.7. Exosome Therapy Market for Dermatological Disorders, 2030-2040 (USD Million)
  • 15.2.8. Exosome Therapy Market for Muscoskeletal Disorders, 2031-2040 (USD Million)
  • 15.2.9. Exosome Therapy Market for Ophthalmic Disorders, Till 2040 (USD Million)
  • 15.2.10. Exosome Therapy Market for Rectal Disorders, Till 2040 (USD Million)
  • 15.2.11. Fistula Tract Exosome Therapy Market, Till 2040 (USD Million)
  • 15.2.12. Intra-articular Exosome Therapy Market, 2031-2040 (USD Million)
  • 15.2.13. Intra-ocular Exosome Therapy Market, Till 2040 (USD Million)
  • 15.2.14. Exosome Therapy Market Geographical Distribution, Till 2040 (USD Million)
  • 15.2.15. Erciyes University's Drug: Sales Forecast, Till 2040 (USD Million)
  • 15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)
  • 15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million)
  • 15.2.18. Trehan University of Medical Sciences' Drug: Sales Forecast, Till 2040 (USD Million)
  • 15.2.19. ReNeuron' Drug: Sales Forecast, Till 2040 (USD Million)

16. EXECUTIVE INSIGHTS

• 16.1. Capricor Therapeutics
  • 16.1.1. Company Snapshot
  • 16.1.2. Interview Transcript: Chief Business Officer
• 16.2. Exogenus Therapeutics
  • 16.2.1. Company Snapshot
  • 16.2.2. Interview Transcript: R&D and Innovation Manager
• 16.3. ILIAS Biologics
  • 16.3.1. Company Snapshot
  • 16.3.2. Interview Transcript: Chief Business Officer

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS